SG Americas Securities LLC Acquires 22,482 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Posted by on Aug 9th, 2023

SG Americas Securities LLC lifted its position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) by 305.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,843 shares of the biotechnology company’s stock after purchasing an additional 22,482 shares during the quarter. SG Americas Securities LLC’s holdings in Aclaris Therapeutics were worth $241,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ACRS. JPMorgan Chase & Co. boosted its holdings in shares of Aclaris Therapeutics by 20.0% in the 1st quarter. JPMorgan Chase & Co. now owns 44,650 shares of the biotechnology company’s stock worth $770,000 after purchasing an additional 7,448 shares in the last quarter. MetLife Investment Management LLC boosted its holdings in shares of Aclaris Therapeutics by 58.5% in the 1st quarter. MetLife Investment Management LLC now owns 26,282 shares of the biotechnology company’s stock worth $453,000 after purchasing an additional 9,700 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Aclaris Therapeutics by 18.1% in the 1st quarter. Rhumbline Advisers now owns 55,194 shares of the biotechnology company’s stock worth $952,000 after purchasing an additional 8,469 shares in the last quarter. Allianz Asset Management GmbH boosted its holdings in shares of Aclaris Therapeutics by 44.2% in the 1st quarter. Allianz Asset Management GmbH now owns 81,965 shares of the biotechnology company’s stock worth $1,413,000 after purchasing an additional 25,125 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Aclaris Therapeutics by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 2,728,820 shares of the biotechnology company’s stock worth $47,045,000 after purchasing an additional 10,713 shares in the last quarter.

Aclaris Therapeutics Price Performance

Shares of ACRS stock opened at $8.66 on Wednesday. The business has a 50-day moving average of $9.96 and a 200 day moving average of $10.19. The stock has a market capitalization of $612.09 million, a PE ratio of -6.01 and a beta of 0.59. Aclaris Therapeutics, Inc. has a 1-year low of $5.77 and a 1-year high of $18.96.

Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.03. Aclaris Therapeutics had a negative return on equity of 46.40% and a negative net margin of 312.32%. The firm had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.90 million. During the same quarter in the prior year, the company earned ($0.31) EPS. The business’s revenue was up 26.7% compared to the same quarter last year. Analysts anticipate that Aclaris Therapeutics, Inc. will post -1.81 EPS for the current year.

Insider Transactions at Aclaris Therapeutics

In related news, insider Joseph Monahan sold 6,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of $10.28, for a total transaction of $61,680.00. Following the completion of the transaction, the insider now owns 141,724 shares of the company’s stock, valued at approximately $1,456,922.72. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 5.50% of the company’s stock.

Wall Street Analysts Forecast Growth

ACRS has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $43.00 price objective on shares of Aclaris Therapeutics in a report on Tuesday. StockNews.com began coverage on Aclaris Therapeutics in a report on Thursday, May 18th. They set a “sell” rating for the company. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Aclaris Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

View Our Latest Stock Report on Aclaris Therapeutics

About Aclaris Therapeutics

(Free Report)

Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.

See Also

Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report).

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.